SUMMARY Studies in the rat jejunum in vivo have shown that 5-hydroxytryptamine (5-HT) causes secretion of fluid and luminal release of prostaglandin (PG) E2. These effects can be blocked by indomethacin and ketanserin, which suggests that PGE2 may be an important intermediate in the transduction mechanism leading to 5-HT induced fluid secretion. To test this hypothesis in man 'steady state' perfusions (9 ml/min) were done in eight healthy volunteers using the triple lumen technique. The proximal jejunum was perfused with Ringer's solution which contained 11Cr-EDTA as a non-absorbable marker. Before and after the administration of indomethacin ( 
effects of exogenous 5-HT (10 [ig/kg/min iv) on jejunal net transport of fluid and electrolytes and jejunal flow rate (JFR) of PGE2 were measured in 15-min periods for 2X60 minutes after a 60 minute control period. 5-HT reversed fluid and electrolyte absorption into profuse secretion (p<0 01, Duncan's multiple range test) and significantly increased JFR of PGE2 (p<001). Indomethacin partly restored fluid and electrolyte absorption (p<0.01) and inhibited JFR of PGE2 (p<0 05). These results provide further evidence in favour of the theory that PGs are involved in 5-HT induced intestinal fluid secretion.
It is generally accepted that 5-hydroxytryptamine (5- HT) induces calcium dependent intestinal fluid and electrolyte secretion,'-' possibly through activation of phosphatidylinositol turnover, but (Fig. 2) .
FLOW RATE OF PROSTAGLANDIN E2
The fasting jejunal flow rate of PGE2 at the proximal aspiration port was low during control periods (0. ( Fig. 3) .
ADVERSE EFFECTS
The infusion of 5-HT caused tenderness and redness at the infusion site and in a single case venous spasm, which necessitated a change of the infusion site. The alterations in systolic blood pressure observed during 5-HT infusion were transient and did not exceed 10 mmHg. No significant effect on heart rate was observed. All participants, but three, experienced nausea and slight abdominal discomfort. The administration of indomethacin transiently intensified nausea in all subjects and provoked vomiting in a few cases, but within a few minutes the abdominal symptoms were relieved. and that 5-HT requires a paracellular mediator to elicit the final secretory response. In the morphine withdrawal syndrome observed in the rat the intestinal secretion is mediated by 5-HTP through stimulation of local PG formation in the absence of increased mucosal cyclic AMP contents.' The secretion of fluid and the release of PGE2 are inhibited by the specific 5-HT2-receptor antagonist, ketanserin, and the cyclooxygenase-inhibitor, indomethacin, without affecting the release of Intestinal fluid secretion mediated by 5 
